Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Bought by Torray Investment Partners LLC

Torray Investment Partners LLC raised its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 17.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 19,166 shares of the medical equipment provider’s stock after acquiring an additional 2,788 shares during the period. Torray Investment Partners LLC’s holdings in Lantheus were worth $1,715,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of LNTH. Groupama Asset Managment acquired a new stake in Lantheus in the 3rd quarter valued at about $439,000. Swedbank AB raised its holdings in Lantheus by 53.3% in the 4th quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider’s stock valued at $99,054,000 after acquiring an additional 385,000 shares during the last quarter. Janus Henderson Group PLC raised its holdings in Lantheus by 7.7% in the 3rd quarter. Janus Henderson Group PLC now owns 3,588,571 shares of the medical equipment provider’s stock valued at $393,844,000 after acquiring an additional 257,022 shares during the last quarter. Massachusetts Financial Services Co. MA acquired a new stake in Lantheus in the 3rd quarter valued at about $25,955,000. Finally, Point72 DIFC Ltd acquired a new stake in Lantheus in the 3rd quarter valued at about $23,001,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Stock Performance

Lantheus stock opened at $94.86 on Tuesday. Lantheus Holdings, Inc. has a fifty-two week low of $56.44 and a fifty-two week high of $126.89. The firm has a 50 day moving average price of $89.89 and a 200 day moving average price of $96.73. The company has a market capitalization of $6.50 billion, a PE ratio of 15.78 and a beta of 0.44.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The company had revenue of $391.11 million during the quarter, compared to analyst estimates of $376.61 million. As a group, equities research analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Insider Activity at Lantheus

In related news, Director James H. Thrall sold 1,000 shares of Lantheus stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the sale, the director now owns 33,207 shares in the company, valued at approximately $3,146,695.32. This trade represents a 2.92 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 1.50% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. StockNews.com downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. The Goldman Sachs Group assumed coverage on shares of Lantheus in a report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price target for the company. JMP Securities restated a “market outperform” rating and set a $112.00 price target on shares of Lantheus in a report on Tuesday, January 14th. Finally, Truist Financial raised their price target on shares of Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a report on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $132.86.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.